High levels do not necessarily correlate with other established axonal damage biomarkers (for example tau) and are not specific enough to be diagnostic for particular disorders, as raised levels occur in many diseases including ALS, adrenoleukodystrophy, frontotemporal dementia, and autoimmune encephalitis. This evidence concerns the gene MAPT and adrenoleukodystrophy.